EGFR and lung adenocarcinoma: We expressed hyBRET-ERK in EGFR inhibitor-sensitive PC9 lung adenocarcinoma cells27, treated the cells with gefitinib for one day, and quantified the ERK activity by means of the BRET ratio and the living cells by the total luminescent counts (Fig. 4c–f).